MicroRNAs (miRNA or miR) are small ∼21--23 nucleotide noncoding RNAs that play a crucial role in downregulating the translation of select target genes. Because an individual miRNA can target up to hundreds of mRNAs (mRNA), alterations in miRNA expression have been linked to many human diseases.^[@ref1]^ In cancer, global downregulation of tumor suppressor miRNAs (TS-miRs) is commonly observed and has been demonstrated to be a causative feature in tumorigenesis.^[@ref2]−[@ref4]^ Loss can stem from genetic mutation or deletion, promoter methylation, or dysregulation of miRNA biogenesis.^[@ref2]^ Of these mechanisms, alteration of global miRNA biogenesis is receiving increased attention due to recent findings demonstrating the critical role that miR-binding proteins (miR-BPs) play in the inhibition of this process, ultimately stimulating TS-miR degradation and cancer development.^[@ref5]−[@ref8]^

The canonical biogenesis of a mature miRNA derives from two intermediate hairpin loops, nuclear pri-miRNA and cytosolic pre-miRNA, and is mediated by the RNase III enzymes, Drosha and Dicer, respectively.^[@ref9]^ Only mature miRNAs function in gene silencing.^[@ref9]^ Importantly, the hairpin loop motif of pri- and pre-miRNAs has been found to be a critical regulatory element serving as a docking site for miR-BPs that affect maturation. The most well-characterized is the let-7--Lin28 interaction, where Lin28 protein functions as an inhibitor of let-7 maturation by binding to the hairpin loop of pri- and pre-let-7.^[@ref10]−[@ref12]^ Two isoforms of Lin28 exist in humans, Lin28A and Lin28B (collectively referred to as Lin28).^[@ref12]^ Both interact similarly and use three RNA-binding domains to regulate let-7 maturation: an N-terminal cold shock domain and two CCHC zinc knuckle domains.^[@ref13]^ The binding affinity (*K*~d~) of full-length Lin28 for pre-let-7 is between 33--65 nM, and the zinc knuckle domains have been found to afford the selectivity of Lin28 for let-7 and contribute significantly to its binding affinity.^[@ref14],[@ref15]^

The let-7 family plays an important role in cancer development and progression by downregulating cellular oncogenes including RAS and its mutant isoforms and Myc.^[@ref16]^ Lin28 binding recruits terminal uridylyltransferases (TUTases), which polyuridylylate the 3′ terminus of pre-let-7 to inhibit Dicer processing and promote let-7 degradation.^[@ref17]^ Loss of let-7 through this mechanism has been observed in at least 15% of all human cancers, including lung, breast, liver, esophageal, stomach, ovarian, prostate, and colon cancers, neuroblastoma, and chronic lymphocytic leukemia.^[@ref3],[@ref4],[@ref12],[@ref18]^ Related, reduced let-7 levels have been found to correlate with poor prognosis and decreased patient survival.^[@ref18]^ Importantly, delivery of a let-7 mimic or knockdown of Lin28 has been shown to reduce tumor growth *in vivo*,^[@ref19]−[@ref23]^ indicating the potential for anticancer agents targeted at restoring physiological levels of this TS-miR.

Over the past few years, our laboratory has developed high-throughput screening (HTS) technology called catalytic enzyme-linked click chemistry assay, or cat-ELCCA.^[@ref24]−[@ref27]^ Key advantages of this approach for HTS include its increased sensitivity due to catalytic signal amplification, robustness, and negligible compound interference in comparison to traditional fluorescence-based assays due to added washing steps.^[@ref27],[@ref28]^ To date, we have applied cat-ELCCA for the discovery of pre-miRNA-selective small molecule probes^[@ref29]^ and inhibitors of an acyltransferase^[@ref30]^ and protein--protein interactions (PPI).^[@ref31]^ Herein, we describe further expansion of cat-ELCCA for the discovery of inhibitors of miR--miR-BP interactions, namely, the pre-let-7--Lin28 interaction. Through these efforts, we have developed a robust screening platform for RNA--protein interactions and used this approach to discover a new chemotype capable of inhibiting a RNA-binding protein.

A scheme of cat-ELCCA for the pre-let-7--Lin28 interaction is shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A. In brief, drawing inspiration from PPI cat-ELCCA,^[@ref31]^ murine Lin28A was first expressed as a N-terminal HaloTag fusion protein, labeled with biotin, and immobilized into the wells of a streptavidin-coated microtiter plate. Contrary to our Dicer-mediated pre-miRNA maturation cat-ELCCA,^[@ref25],[@ref26],[@ref29]^ we chose to immobilize Lin28A, as preliminary studies revealed significantly enhanced immobilization efficiency of protein in comparison to RNA (data not shown). Following Lin28A immobilization, the wells were then incubated with pre-let-7d containing a 5′-*trans*-cyclooctene (TCO) click chemistry handle. Of note, this pre-let-7 isoform was chosen as its binding to Lin28 has been well-characterized.^[@ref13]^ Importantly, binding of these modified substrates was successfully confirmed via an electrophoretic mobility shift assay (EMSA) ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)). Interaction of pre-let-7d with Lin28A was detected via click chemistry with methyltetrazine-labeled horseradish peroxidase (mTet-HRP), followed by treatment with a HRP substrate and measurement of chemiluminescence signal. As shown in [Figure S1B--D](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf), the assay exhibited a *Z*′ factor^[@ref32]^ of \>0.5 using automated liquid handling, was dependent on the concentration of TCO--pre-let-7d (*K*~d,app~ of 106 nM), and was amenable to competition using unlabeled prelet-7d.

![cat-ELCCA for the pre-let-7d--Lin28 miR--miR--BP interaction. (A) Assay scheme. (B) HTS campaign.](ml-2018-00126e_0001){#fig1}

Encouraged by these promising results, we proceeded to HTS at the University of Michigan Center for Chemical Genomics. Our HTS assay protocol is summarized in [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf) and was performed using 384-well, high capacity, white streptavidin-coated well plates. In total, 127,007 small molecules were screened at 25 μM from the LOPAC (1280), Prestwick (1280), Maybridge (23 552), ChemDiv (100 000), and University of Michigan Chemistry (895) libraries. The assay performed excellently with a campaign *Z*′ factor of 0.5 and average plate *Z*′ factor of 0.71 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). Using primary hit criteria of ≥25% inhibition, 1468 compounds were selected for triplicate analysis, yielding a hit rate of 1.1%. Following hit confirmation, 181 molecules were selected that exhibited inhibition at ≥3SD by plate from the negative controls (12% of hits). Compounds were then analyzed in dose response; 136 molecules (75% of confirmed hits) were active with inhibitory potencies ranging from IC~50~ of 0.01--100 μM.^[@ref33]^

After removing known promiscuous hits (i.e., PAINS)^[@ref34]^ and filtering for reactivity issues and tractable medicinal chemistry scaffolds, 20 compounds were selected for repurchase ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)). While 10 of the purchased compounds were found to retain activity ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)), only two showed concentration-responsive activity in both cat-ELCCA (IC~50~ values of 8.3 and 10.3 μM (*n*~H~ = −1.3 and −1.2), respectively) and EMSA: the *N*,*N*′-(1,2-phenylene)-dibenzenesulfonamide derivatives **CCG-233094** and **CCG-234459** ([Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and [S5](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)). These compounds were also found to inhibit a cat-ELCCA of the pre-let-7d--Lin28B interaction with similar IC~50~ values ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)). Additionally, they showed inhibition of the interaction between Lin28A and other pre-let-7 isoforms ([Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)). Through additional analysis, the compounds were found to function through direct interaction with Lin28, as dose-responsive binding was only observed with the protein ([Figure S8](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)), not pre-let-7d ([Figure S9](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)). Importantly, these compounds showed insignificant inhibition of Dicer-mediated pre-let-7d maturation, in addition to a cat-ELCCA-based PPI assay ([Figure S10](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf)), providing a promising selectivity profile for our hits.

![HTS hits for the pre-let-7d--Lin28A interaction. (A) Compound structures. (B) IC~50~ curves from 0--500 μM.](ml-2018-00126e_0002){#fig2}

In order to further profile this scaffold, we performed initial structure--activity relationship (SAR) studies by catalogue, and 18 derivatives were available for purchase from commercial vendors. While fluoro-substituted compounds, aside from **CCG-233094**, could not be obtained, 11 unsubstituted derivatives were tested. As shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, all analogues were active, showing variable inhibitory potencies of 10--62 μM. Several methyl-substituted analogues of **CCG-234459** were also purchased and analyzed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Again, each was active with IC~50~ values ranging between 11--28 μM. Inhibition curves for both sets of compounds are shown in [Figure S11](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00126/suppl_file/ml8b00126_si_001.pdf). Although none of the compounds showed enhanced potency over the parent compounds, these studies revealed that a combination of a *meta*-electron-withdrawing group and *para*-fluoro or -methyl substitution was optimal for maintaining inhibitory activity and that substituents on the center ring are not required. Additionally, two inactive molecules were identified: monosulfonamide **3** and *N*,*N*′-(1,3-phenylene)dibenzenesulfonamide **4** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), demonstrating the necessity of the bis-sulfonamide and its 1,2-orientation for activity. This was further emphasized through synthetic derivatives **5** and **6** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), which were also found to be inactive.

###### SAR by Catalogue of *N*,*N*′-(1,2-Phenylene)dibenzenesulfonamide Derivatives

![](ml-2018-00126e_0004){#fx1}

  compd            R^1^         R^2^         R^3^   IC~50~ (μM)
  ---------------- ------------ ------------ ------ -------------
  **1a**           H            H            H      32.2
  **1b**           *p*-F        H            H      13.9
  **1c**           *p*-F        *p*-F        H      28.3
  **1d**           *p*-F        *p*-Cl       H      27.3
  **1e**           *p*-F        *p*-OMe      H      17.2
  **1f**           *p*-F        *m*-Cl       H      10.8
  **1g**           *p*-F        *m*-Br       H      16.2
  **1h**           *p*-Cl       *p*-Cl       H      27.5
  **1i**           *p*-Br       *p*-Br       H      17.5
  **1j**           *p*-OMe      *p*-OMe      H      16.7
  **1k**           *p*-NHCOMe   *p*-NHCOMe   H      62.5
  **CCG-234459**   *m*-CF3      *p*-Me       Me     10.3
  **2a**           H            H            Me     28.8
  **2b**           *p*-F        *p*-F        Me     16.2
  **2c**           *p*-F        *p*-Me       Me     11.7
  **2d**           *p*-Cl       *p*-Cl       Me     28.4
  **2e**           *p*-Me       *p*-Me       Me     14.1

![Structures of inactive scaffolds.](ml-2018-00126e_0003){#fig3}

To further probe the SAR of our discovered scaffold, additional derivatives were synthesized. Because the *meta*-chloro analogue **1f** retained activity similar to that of our initial hits, we first examined if *meta*-substitution was tolerated on both rings. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, the symmetric molecule **7a** showed an improved IC~50~ value of 5.7 μM. Similar inhibitory activity was observed with the asymmetric methyl-substituted analogue **7b**. As our screening hits contained *para*-methyl substituents, we next explored its combination with a *meta*-chloro substituent. Importantly, compounds **7c** and **7d**, containing unsubstituted or fluoro-substituted center rings, both showed further improvement in activity (IC~50~ values of 2.3 and 3.7 μM, respectively). Thus, we are hopeful that this series can be further optimized through future efforts in structure-based drug design.

###### Additional SAR of *N*,*N*′-(1,2-Phenylene)dibenzenesulfonamide Derivatives
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  compd    R^1^             R^2^             R^3^   IC~50~ (μM)
  -------- ---------------- ---------------- ------ -------------
  **7a**   *m*-Cl           *m*-Cl           H      5.7
  **7b**   *m*-Cl           *m*-Cl           Me     4.3
  **7c**   *m*-Cl, *p*-Me   *m*-Cl, *p*-Me   H      2.3
  **7d**   *m*-Cl, *p*-Me   *m*-Cl, *p*-Me   F      3.7

In conclusion, using the adaptability of cat-ELCCA, we have developed new assay technology for analyzing RNA--protein interactions. Using this approach, we subsequently performed HTS and identified a new class of inhibitor for the pre-let-7--Lin28 interaction.^[@ref35]−[@ref37]^ As the important roles that RNA-binding proteins play in regulating RNA biology are emerging,^[@ref38],[@ref39]^ there is a need for methods by which to discover small molecule chemical probes and drug leads for these targets. Similar to PPIs, RNA--protein interaction assays have relied on traditional methods such as fluorescence polarization,^[@ref40]^ FRET,^[@ref35],[@ref36]^ or AlphaScreen.^[@ref41]^ Although useful for high-throughput experimentation, these assays can be limited by size requirements and the need for structural information for assay design. Because cat-ELCCA is amenable to HTS, utilizes a simple N- or C-terminus protein modification strategy, and does not require structural information, it should be an enabling tool for these future research endeavors. While there are many benefits to this new technology, limitations include the need for washing steps, which can hinder throughput and restrain its use to interactions with binding affinities ≤1.0 μM, similar to ELISA. Efforts are currently underway to engineer cat-ELCCA as a homogeneous chemiluminescence-based assay.
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